IXICO (LSE:IXI) Pre-Tax Income : £-1.36 Mil (TTM As of Sep. 2023)

View and export this data going back to 1996. Start your Free Trial

What is IXICO Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. IXICO's pretax income for the six months ended in Sep. 2023 was £-0.48 Mil. Its pretax income for the trailing twelve months (TTM) ended in Sep. 2023 was £-1.36 Mil. IXICO's pretax margin was -13.78%.

During the past 13 years, IXICO's highest Pretax Margin was 11.94%. The lowest was -50900.00%. And the median was -17.56%.

IXICO Pre-Tax Income Historical Data

The historical data trend for IXICO's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IXICO Pre-Tax Income Chart

IXICO Annual Data

Trend

Sep13

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Pre-Tax Income

Get a 7-Day Free Trial

0.37

0.86

1.10

0.89

-1.36

IXICO Semi-Annual Data
	Sep13	Mar14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Pre-Tax Income	Get a 7-Day Free Trial															0.46	0.15	0.73	-0.88	-0.48

Competitive Comparison of IXICO's Pre-Tax Income

For the Biotechnology subindustry, IXICO's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IXICO's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IXICO's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where IXICO's Pre-Tax Income falls into.

IXICO Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

IXICO's Pretax Income for the fiscal year that ended in Sep. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-1.437	+	0	+	-0.029	+	0.105	+	0
	=	-1.36

IXICO's Pretax Income for the quarter that ended in Sep. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-0.524	+	0	+	-0.014	+	0.061	+	5.5511151231258E-17
	=	-0.48

Pre-Tax Income for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-1.36 Mil.

IXICO (LSE:IXI) Pre-Tax Income Explanation

IXICO's Pretax Margin for the quarter that ended in Sep. 2023 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-0.477	/	3.462
	=	-13.78%

During the past 13 years, IXICO's highest Pretax Margin was 11.94%. The lowest was -50900.00%. And the median was -17.56%.

IXICO Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of IXICO's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

IXICO (LSE:IXI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IXICO PLC (LSE:IXI) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

PHYOF:USA

Address

15 Long Lane, 4th Floor, Griffin Court, London, GBR, EC1A 9PN

Website

https://www.ixico.com

IXICO PLC is a UK-based company engaged in providing clinical trial services and technology to evaluate imaging endpoints to pharmaceutical companies. Its therapeutic areas include Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis, Progressive Supranuclear Palsy, and Other Rare Neurological Diseases. Services offered by the company are Early Phase Clinical Development, Late Phase Clinical Development, Post-Marketing, and Consultancy. The company's geographical segments include the United States, Switzerland, the United Kingdom, the Netherlands, Ireland and other- Europe. The Company work with healthcare organizations across the entire clinical research journey, for drug development analytics, medical imaging operations and post-marketing surveillance.

IXICO (LSE:IXI) Headlines

No Headlines